No Data
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $29
Strategic Realignment and Pipeline Potential Drive Buy Rating for Intellia Therapeutics
The gene editing company Intellia Therapeutics (NTLA.US) will cut 27% of its workforce and halt the NTLA-3001 project.
Intellia Therapeutics stated that it plans to focus its resources on the development of candidate drugs NTLA-2002 and nex-z, and will cease the development of NTLA-3001, which will result in approximately 27% of the company being laid off.
Intellia Therapeutics to Lay Off 27% of Workers in Reorganization
Intellia Therapeutics Announces Retirement of CSO Laura Sepp-Lorenzino
Intellia Therapeutics: Phase 3 HAELO Study to Complete Enrollment in 2H25
